Global, regional and national estimates of influenza-attributable ischemic heart disease mortality

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,1 MB, PDF-dokument

  • Sandra S. Chaves
  • Joshua Nealon
  • Katrin G. Burkart
  • Daniel Modin
  • Biering-Sørensen, Tor
  • Justin R. Ortiz
  • Victor M. Vilchis-Tella
  • Lindsey E. Wallace
  • Gregory Roth
  • Cedric Mahe
  • Michael Brauer

Background: Influenza virus infection is associated with incident ischemic heart disease (IHD) events. Here, we estimate the global, regional, and national IHD mortality burden attributable to influenza. Methods: We used vital registration data from deaths in adults ≥50 years (13.2 million IHD deaths as underlying cause) to assess the relationship between influenza activity and IHD mortality in a non-linear meta-regression framework from 2010 to 2019. This derived relationship was then used to estimate the global influenza attributable IHD mortality. We estimated the population attributable fraction (PAF) of influenza for IHD deaths based on the relative risk associated with a given level of weekly influenza test positivity rate and multiplied PAFs by IHD mortality from the Global Burden of Disease study. Findings: Influenza activity was associated with increased risk of IHD mortality across all countries analyzed. The mean PAF of influenza for IHD mortality was 3.9% (95% uncertainty interval [UI] 2.5–5.3%), ranging from <1% to 10%, depending on country and year. Globally, 299,858 IHD deaths (95% UI 191,216–406,809) in adults ≥50 years could be attributed to influenza, with the highest rates per 100,000 population in the Central Europe, Eastern Europe and Central Asia Region (32.3; 95% UI 20.6–43.8), and in the North Africa and Middle East Region (26.7; 95% UI 17–36.2). Interpretation: Influenza may contribute substantially to the burden of IHD. Our results suggest that if there were no influenza, an average of 4% of IHD deaths globally would not occur. Funding: Collaborative study funded by Sanofi Vaccines.

OriginalsprogEngelsk
Artikelnummer101740
TidsskriftEClinicalMedicine
Vol/bind55
Antal sider10
ISSN2589-5370
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The study was funded by Sanofi Vaccines. Three authors (S.S.C., J.N., C.M.) are employees of Sanofi and were involved in formulating the study question, study design, interpretation of the results. K.G.B., V.M.V.-T., L.E.W. and M.B. had access to the data and were responsible for data analysis with input from all the other co-authors. S.S.C. wrote the first draft of the manuscript. All authors critically reviewed the manuscript and contributed to the decision to publish its final version.

Funding Information:
The authors would like to thank all the countries that shared cause of death data with the Institute for Health Metrics and Evaluation, allowing for this analysis. This study received funding from Sanofi Vaccines , Lyon, France.

Funding Information:
The authors would like to thank all the countries that shared cause of death data with the Institute for Health Metrics and Evaluation, allowing for this analysis. This study received funding from Sanofi Vaccines, Lyon, France.

Publisher Copyright:
© 2022 The Author(s)

ID: 331789588